info@epichembio.eu + 34 986 812 316
Adobe Photoshop PDF

miR-194-5p/BCLAF1 deregulation in AML tumorigenesis

March 20, 2017

L Altucci and HG Stunnenberg teams show here that the balance between miR-194-5p and its transcription factor 1 (BCLAF1) regulates differentiation and survival of normal hematopoietic progenitors.

Leukemia: miR-194-5p/BCLAF1 deregulation in AML tumorigenesis

Abstract

Deregulation of epigenetic mechanisms, including microRNA, contributes to leukemogenesis and drug resistance by interfering with cancer-specific molecular pathways. Here, we show that the balance between miR-194-5p and its newly discovered target BCL2-associated transcription factor 1 (BCLAF1) regulates differentiation and survival of normal hematopoietic progenitors. In acute myeloid leukemias this balance is perturbed, locking cells into an immature, potentially ‘immortal’ state. Enhanced expression of miR-194-5p by treatment with the histone deacetylase inhibitor SAHA or by exogenous miR-194-5p expression re-sensitizes cells to differentiation and apoptosis by inducing BCLAF1 to shuttle between nucleus and cytosol. miR-194-5p/BCLAF1 balance was found commonly deregulated in 60 primary acute myeloid leukemia patients and was largely restored by ex vivo SAHA treatment. Our findings link treatment responsiveness to re-instatement of miR-194-5p/BCLAF1 balance.



More Scientific Publications >>>>

Cost UE